Raising Capital for AI-Native Adaptive Radiotherapy, MR-Linac, Auto-Contouring, SBRT/SABR Planning, FLASH, Proton, Theranostics, Lu-177/Ac-225 Radioligand Therapy, PSMA/DOTATATE/FAP-Targeted Isotope Manufacturing & Cyclotron-Reactor Supply-Chain Startups
AI-native adaptive-radiotherapy, MR-Linac, CT-Linac, cone-beam-CT-CBCT, auto-contouring-OAR-Organs-At-Risk, auto-segmentation-CTV-GTV-PTV, SBRT-Stereotactic-Body-Radiation, SABR-Stereotactic-Ablative, intensity-modulated-radiation-IMRT, volumetric-modulated-arc-VMAT, FLASH-radiotherapy-ultra-high-dose-rate, proton-therapy-pencil-beam, carbon-ion, BNCT-boron-neutron-capture, theranostics, radioligand-therapy-RLT, Lu-177-lutetium, Ac-225-actinium, Y-90-yttrium, I-131-iodine, Ga-68-gallium, F-18-fluorine, Cu-64-copper, Pb-212-lead, At-211-astatine, PSMA-prostate-specific-membrane-antigen, DOTATATE-somatostatin, FAP-fibroblast-activation-protein, HER2, CAIX, integrin-alpha-v-beta-6, cyclotron, reactor-produced-isotope, generator-produced, supply-chain-cold-chain-half-life-logistics is one of the highest-signal AI-oncology, medtech, radiopharma, specialty-pharma categories for 2026 — validated by Novartis-Pluvicto-Lu-177-vipivotide-tetraxetan-FDA-approved-Mar-2022-metastatic-castration-resistant-prostate-cancer-mCRPC-expanded-Mar-2025-pre-taxane, Novartis-Lutathera-Lu-177-DOTATATE-FDA-approved-Jan-2018-gastroenteropancreatic-neuroendocrine, Bristol-Myers-Squibb-RayzeBio $4.1B-Dec-2023-Ac-225-RYZ101, Eli-Lilly-Point-Biopharma $1.4B-Oct-2023-PNT2002-PNT2003, AstraZeneca-Fusion-Pharmaceuticals $2.4B-Mar-2024-Ac-225-FPI-2265, Novartis-Mariana-Oncology $1B-May-2024-Ac-225, Sanofi-Orano-Med, Bayer-Xofigo-Ra-223, Curium, Lantheus $NASDAQ:LNTH-Pylarify-F-18-piflufolastat, Telix-Illuccix-Ga-68, POINT-BioPharma-Lilly, Perspective-Therapeutics, Clarity-Pharmaceuticals, ITM-Isotope-Technologies-Munich, Ariceum, Convergent-Therapeutics, Elekta $STO:EKTA-B-Unity-MR-Linac, Varian-Siemens-Healthineers-Ethos-adaptive, RefleXion-SCINTIX-biology-guided-FDA-cleared, Accuray $NASDAQ:ARAY-CyberKnife-Radixact, ViewRay-Chapter-11-Jul-2023-legacy-MRIdian-acquired-BeiGene, MIM-Software-GE-HealthCare-May-2024-$500M+, Radformation-adj, Limbus-AI-Varian-May-2023, Siris-Medical, Manteia-Data-Wave-2, Oncora-Medical, Kaiku-Health-Elekta as the credible-scale AI-adaptive-RT, theranostics stack. Founders here underwrite on FDA-510(k), PMA, peer-reviewed multi-center, ASTRO-American-Society-Radiation-Oncology, AAPM-American-Association-Physicists-Medicine, ESTRO-European-Society-Therapeutic-Radiology-Oncology, NCCN-guideline, CMS-APM-CY-2025, isotope-supply-security benchmark — not vanity 'AI-for-radiation-oncology' claims without an FDA clearance, peer-reviewed dosimetric validation, or secured Lu-177/Ac-225 supply.
Why 2026 is different
Four unlocks: (1) Novartis-Pluvicto (Lu-177-PSMA)-FDA-Mar-2022 metastatic-castration-resistant-prostate-cancer, expanded-Mar-2025 pre-taxane label, PSMAfore Phase-III positive, Novartis-Lutathera (Lu-177-DOTATATE) $500M+ 2024-run-rate proved theranostics, radioligand-therapy as a scaled, reimbursed, supply-constrained oncology modality — no longer research-only. (2) The $8B+ 2023-2024 pharma-radiopharma M&A wave — Bristol-Myers-Squibb-RayzeBio $4.1B-Dec-2023, Eli-Lilly-Point-Biopharma $1.4B-Oct-2023, AstraZeneca-Fusion-Pharmaceuticals $2.4B-Mar-2024, Novartis-Mariana-Oncology $1B-May-2024, Sanofi-Orano-Med — set the strategic-exit path for Ac-225 alpha-emitter platforms and made every top-15 oncology pharma a captive buyer. (3) CMS-Medicare-Part-B-Radiopharmaceutical-Payment-Reform-CY-2025-Nov-2024 introduced the High-Cost-Radiopharmaceutical-Payment-Policy separating high-cost radiopharmaceuticals from the APC bundle at ASP+6% — the first Medicare payment framework that meaningfully reimburses $30K-$200K Lu-177/Ac-225 doses, plus CMS-Enhancing-Oncology-Model-EOM-Jul-2023 mandating episode-based accountability at 25+ practices. (4) FDA-cleared adaptive-RT, biology-guided-RT — Varian-Ethos-adaptive-CBCT, Elekta-Unity-MR-Linac, RefleXion-SCINTIX-PET-guided-biology-guided-2023, MIM-Software-GE-HealthCare-May-2024-$500M+, Limbus-AI-Varian-May-2023, Radformation — collapsed contouring, planning, adaptation from hours to minutes, making daily adaptive workflows a hard-gated buying criterion, while Ac-225-U-233-DOE-Oak-Ridge-BWXT, ANSTO-Lu-177-n.c.a, NorthStar-Mo-99, TerraPower-Isotopes, Nusano supply-security became a Series-A gating item after 2022-2024 Lu-177 shortages.
Realistic capital stack
Seed $2-8M for first-target-validation, first-in-vivo-preclinical, first-Ga-68-imaging-companion-diagnostic, first-cGMP-CMC-CMO-partnership, first-FDA-Pre-IND, first-cyclotron-reactor-supply-agreement (Aktis-Oncology-early, Convergent-early, Ariceum-early, Precirix-early, Perspective-Therapeutics-early, Radionetics-early, Full-Life-Technologies-early). Series A/B/C $30-200M for first-in-human Phase-1, Phase-1b, dose-escalation, Ga-68-companion-approval, FDA-Fast-Track, Orphan-Drug, Breakthrough-Therapy, cGMP-manufacturing, Lu-177-n.c.a-supply, Ac-225-supply, Radionuclide-Master-File, regulatory-CMC, Global-Phase-2/3 (POINT-Biopharma-Lilly-$1.4B-Oct-2023, Fusion-AZ-$2.4B-Mar-2024, RayzeBio-BMS-$4.1B-Dec-2023, Mariana-Novartis-$1B-May-2024, Aktis-Oncology-$84M-Series-B-Nov-2022-Third-Rock-Novartis-Bristol-Myers-Squibb, Ariceum-$47M-Series-A, Convergent-Therapeutics-$90M-Series-A-Jan-2023-RA-Capital, Perspective-Therapeutics-$87M-May-2024, Radionetics-Oncology-$52.5M-Feb-2024, Radformation-adj, Limbus-AI-Varian-acquired-May-2023, MIM-GE-HealthCare-acquired-May-2024). Growth, IPO, PE, strategic $200M-$10B+ (Novartis-Pluvicto-Lutathera-$5B+-2027E, BMS-RayzeBio-$4.1B, Lilly-Point-$1.4B, AZ-Fusion-$2.4B, Novartis-Mariana-$1B, Sanofi-Orano-Med, Bayer-Xofigo, Curium-CapVest-2021, Lantheus $NASDAQ:LNTH, Telix $ASX:TLX, ITM-Isotope-Technologies, Perspective $NYSE:CATX, Clarity $ASX:CU6, Elekta $STO:EKTA-B, Varian-Siemens-Healthineers-$16.4B-2020, Accuray $NASDAQ:ARAY, RefleXion-$115M-Series-C-Feb-2024-KKR-Sofinnova-T-Rowe, MIM-Software-GE-HealthCare-May-2024-$500M+). Non-dilutive material — DOE-Isotope-Program-Oak-Ridge-Los-Alamos-Brookhaven, BWXT-Medical-DOE-Ac-225, ARPA-H, NIH-NCI, NIH-SBIR-STTR, Cancer-Moonshot-2.0, EU-Horizon-Europe-Cancer-Mission, IAEA-Rays-of-Hope, ARPA-H-Advanced-Research-Projects-Agency-Health, Wellcome-Cancer-Research-UK, CPRIT-Cancer-Prevention-Research-Institute-Texas, Prostate-Cancer-Foundation.
Common failure modes
Overclaiming target-affinity, tumor-uptake, tumor-to-background, Kd, kd, IC50, dosimetry, Bq/g, Gy, BED, TCP, NTCP, overall-survival, progression-free-survival without FDA-IND, Phase-1, Phase-1b, dose-escalation, Ga-68-companion-diagnostic-approval, peer-reviewed Red-Journal, Green-Journal, JACMP, JCO, JNM, Lancet-Oncology, NEJM multi-center, cGMP-CMC-CMO, Lu-177-n.c.a-supply, Ac-225-supply-DOE-Oak-Ridge-BWXT-ANSTO, NorthStar-Curium-Nordion, NRC-10-CFR-30-35, Agreement-State, DOT-49-CFR, IATA-DGR-Type-B-package, EU-CTR, Euratom-BSSD-2013/59, IAEA-SSR-6 audited track-record — post-Novartis-Pluvicto-Mar-2022, Lutathera-2018, BMS-RayzeBio-Dec-2023, Lilly-Point-Oct-2023, AZ-Fusion-Mar-2024, Novartis-Mariana-May-2024, CMS-Radiopharmaceutical-Payment-Reform-CY-2025, ViewRay-Chapter-11-Jul-2023 credible-scale bar, operators without FDA-cleared, peer-reviewed multi-center, secured Lu-177/Ac-225 supply, NRC, IATA, EU-MDR, Euratom compliance get flagged by Bain-Life-Sciences, OrbiMed, RA-Capital, Deep-Track, Adage, Redmile, Perceptive, Cormorant, Boxer, Longitude, Sofinnova, Forbion, Third-Rock, Novo-Holdings, Sanofi-Ventures, Lilly-Ventures, Novartis-Venture, BMS-Ventures, AZ-Ventures, Bayer-Leaps, Roche-VF, Pfizer-Ventures, GSK-Ventures, JJDC diligence within 12-18 months. Underestimating isotope-supply — Lu-177-n.c.a ANSTO-HFR-Petten-SCK-CEN, Ac-225-U-233-DOE-Oak-Ridge-BWXT-Los-Alamos-Brookhaven vs Th-229-cyclotron-CERN-MEDICIS-TRIUMF vs reactor-ANSTO — half-life logistics, cGMP-manufacturing, Contract-Manufacturing-Organization-CMO, Radionuclide-Master-File, medical-event-reporting-NRC-10-CFR-35.3045, Written-Directive risk. Building yet-another auto-contouring, treatment-planning, IMRT-QA, patient-portal tool in a market where Elekta-Unity, Varian-Ethos, RaySearch, Philips, Accuray, BrainLab, MIM-GE, Limbus-Varian, Radformation, Manteia, Therapanacea, Mirada, Siris, Oncora already have deep department integration, without a defensible AI, FDA-cleared, ASTRO-guideline, CMS-billable, Ac-225/Lu-177-supply-anchored wedge.
Frequently asked questions
- Is there room for another AI-native adaptive-RT, theranostics or radioligand-therapy startup vs. Novartis Pluvicto-Lutathera, BMS-RayzeBio $4.1B, Lilly-Point $1.4B, AZ-Fusion $2.4B, Novartis-Mariana $1B, Sanofi-Orano, Bayer-Xofigo, Elekta-Unity, Varian-Ethos, RefleXion, MIM-GE, Lantheus, Telix, Perspective, Clarity?
- Yes, at the target, isotope, modality, tumor, geography where incumbents don't have depth. Defensible wedges are (a) target (PSMA-prostate, DOTATATE-somatostatin-neuroendocrine, FAP-fibroblast-activation-protein-pan-tumor, HER2, CAIX-renal, integrin-alpha-v-beta-6, gastrin-releasing-peptide-receptor-GRPR, LAT1, CCK2, Nectin-4, PD-L1, Claudin-18.2, CEACAM5, Trop-2, STEAP1, KLK2, hK2, FGFR, EGFR, MET, TROP2, B7-H3, ROR1), (b) isotope (Lu-177-beta-6.65-days, Ac-225-alpha-9.9-days, Pb-212-alpha-10.6-hours, At-211-alpha-7.2-hours, I-131-beta-8-days, Y-90-beta-64.1-hours, Tb-161-Auger-6.9-days, Cu-67-beta-2.6-days, Cu-64-beta-12.7-hours, Ga-68-diagnostic-68-min, F-18-diagnostic-110-min, Zr-89-diagnostic-78.4-hours, Ra-223-alpha-11.4-days), (c) modality (small-molecule, peptide, antibody, minibody, nanobody-VHH-camelid, DARPin, affibody, bicyclic-peptide, aptamer, cell-therapy-radiolabeled, antibody-drug-conjugate-ADC-radiolabeled, companion-diagnostic, theranostic-pair, adaptive-RT-software, auto-contouring, MR-Linac, biology-guided-PET-guided, FLASH, proton, carbon-ion, BNCT), (d) tumor (prostate-mCRPC, neuroendocrine-NET, renal-cell-RCC, glioblastoma, pancreatic-adenocarcinoma, colorectal, gastric, esophageal, hepatocellular, cholangiocarcinoma, melanoma, breast-triple-negative-HER2, non-small-cell-lung-NSCLC, small-cell-lung-SCLC, ovarian, endometrial, head-neck, sarcoma, pediatric, brain-mets, bone-mets), (e) geography (US, EU-CTR, UK-MHRA, Japan-PMDA, China-NMPA, Australia-TGA, Brazil-ANVISA, India-CDSCO, South-Korea-MFDS, Canada-Health-Canada).
- How do investors underwrite an AI-Native Adaptive Radiation Oncology, Theranostics startup?
- Best-in-class disclosures beat headline uptake claims: FDA-510(k)-PMA-BLA-SaMD-PCCP-Aug-2024, AI-ML-Action-Plan, GMLP, FDA-Life-Cycle-Guidance-Jan-2025, Oncology-Center-of-Excellence, Real-Time-Oncology-Review, Breakthrough-Therapy, Fast-Track, Accelerated-Approval, Project-Optimus, Project-Orbis benchmark, peer-reviewed dosimetric, Dice, Hausdorff, Mean-Surface-Distance, Gamma-3%/3mm, DVH, TCP, NTCP, OS, PFS, LC, CTCAE-v5, EORTC-QLQ-C30, PROMIS published in Red-Journal, Green-Journal, JACMP, PMB, Medical-Physics, Lancet-Oncology, JAMA-Oncology, NEJM, JCO, JNM multi-center validation, ASTRO, AAPM-TG-100-142-218-263-275, NCCN-Category-1, ESTRO-ACROP, ACR-Practice-Parameter, IROC-Houston, RTOG-NRG-Alliance-ECOG-ACRIN, AAPM-MPPG compliance, CMS-EOM-Jul-2023, Radiopharmaceutical-Payment-Reform-CY-2025, High-Cost-Radiopharmaceutical-Payment-Policy, CPT-77000-77435, HCPCS-A9800-Lutathera, A9607-Pluvicto, APC-OPPS, 340B benchmark, isotope-supply Lu-177-n.c.a-ANSTO-HFR-SCK-CEN, Ac-225-DOE-Oak-Ridge-BWXT-Los-Alamos-Brookhaven-CERN-MEDICIS-TRIUMF, Mo-99-Tc-99m-NorthStar-Curium-IRE-Nordion, half-life-cGMP, CMC, DMF, Contract-Manufacturing-Organization benchmark, NRC-10-CFR-Part-20-30-35-40, Agreement-State, Radiation-Safety-Officer, Authorized-User, medical-event-reporting, Written-Directive, DOT-49-CFR, IATA-DGR, IAEA-SSR-6, Type-B-package, EU-MDR-Class-IIb-III, EU-IVDR, EU-CTR, Euratom-BSSD-2013/59, ICRP, MHRA-UKCA, Health-Canada, PMDA, NMPA, TGA, ANVISA compliance.
- Which investors write AI-Native Adaptive Radiation Oncology, Theranostics checks?
- Oncology, medtech, radiopharma, specialty-pharma specialists: Bain Capital Life Sciences (POINT-Biopharma-Lilly, Cerevel, Turning-Point-BMS, Aliada), OrbiMed (Perspective-Therapeutics, Fusion-AZ, POINT-adj, Aktis, Convergent), RA Capital (Fusion, POINT, Perspective, Convergent, Aktis, Radionetics-adj), Deep Track (Fusion, POINT, Aktis), Adage (Fusion, POINT, Aktis), Redmile (POINT, Fusion, Convergent), Perceptive Advisors (POINT, Fusion, Perspective, Aktis, Convergent, Ariceum), Cormorant (POINT, Fusion, Aktis), Boxer Capital (POINT, Fusion, Aktis, Convergent, Radiopharm), Farallon (POINT, Fusion), Longitude Capital (Fusion, Perspective, Precirix-adj, Radionetics), Sofinnova Partners (Ariceum, Precirix, Radiopharm-adj), Forbion (Ariceum, Precirix, Aktis-adj), Andera Partners (Ariceum-adj, Precirix), Third Rock Ventures (Aktis-Oncology, Cerevel, Sonata), Novo Holdings (Ariceum, Aktis, POINT-adj), Sanofi-Ventures (Aktis-adj, Precirix, Full-Life-Technologies), Eli-Lilly-Ventures, Novartis-Venture-Fund, BMS-Ventures, AZ-MedImmune-Ventures, Bayer-Leaps, Roche-Venture, Merck-GHI, Pfizer-Ventures, GSK-Ventures, Johnson-Johnson-Innovation-JJDC. Radiation-oncology-device — Elekta $STO:EKTA-B, Varian-Siemens-Healthineers-$16.4B-2020, Accuray $NASDAQ:ARAY, RefleXion-$115M-Series-C-Feb-2024-KKR-Sofinnova-T-Rowe, MIM-Software-GE-HealthCare-May-2024-$500M+, Limbus-AI-Varian-May-2023, IBA, Mevion, Hitachi, Sumitomo, ProNova. Strategic — Novartis Pluvicto-Lutathera-$5B+-2027E, BMS-RayzeBio-$4.1B, Lilly-Point-$1.4B, AZ-Fusion-$2.4B, Novartis-Mariana-$1B, Sanofi-Orano-Med, Bayer-Xofigo, Curium-CapVest-2021, Lantheus $NASDAQ:LNTH, Telix $ASX:TLX, ITM, Perspective $NYSE:CATX, Clarity $ASX:CU6.
